1. Gene Therapy Successfully Delays Degeneration in a Mouse Model ofPDE6A-Linked Retinitis Pigmentosa (RP43)
- Author
-
Christian Schön, Vithiyanjali Sothilingam, Regine Mühlfriedel, Marina Garcia Garrido, Susanne C. Beck, Naoyuki Tanimoto, Bernd Wissinger, François Paquet-Durand, Martin Biel, Stylianos Michalakis, Mathias W. Seeliger, and null the RD-Cure Consortium
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,genetic structures ,Transgene ,Genetic enhancement ,030105 genetics & heredity ,03 medical and health sciences ,In vivo ,Retinitis pigmentosa ,Genetics ,medicine ,Molecular Biology ,Retina ,biology ,medicine.diagnostic_test ,business.industry ,Therapeutic effect ,medicine.disease ,medicine.anatomical_structure ,Rhodopsin ,biology.protein ,Molecular Medicine ,sense organs ,business ,Electroretinography - Abstract
Retinitis pigmentosa type 43 (RP43) is a blinding disease caused by mutations in the gene for rod phosphodiesterase 6 alpha (PDE6A). The disease process begins with a dysfunction of rod photoreceptors, subsequently followed by a currently untreatable progressive degeneration of the entire outer retina. Aiming at a curative approach via PDE6A gene supplementation, a novel adeno-associated viral (AAV) vector was developed for expression of the human PDE6A cDNA under control of the human rhodopsin promotor (rAAV8.PDE6A). This study assessed the therapeutic efficacy of rAAV8.PDE6A in the Pde6anmf363/nmf363-mutant mouse model of RP43. All mice included in this study were treated with sub-retinal injections of the vector at 2 weeks after birth. The therapeutic effect was monitored at 1 month and 6 months post injection. Biological function of the transgene was assessed in vivo by means of electroretinography. The degree of morphological rescue was investigated both in vivo using optical coherence tomography and...
- Published
- 2017
- Full Text
- View/download PDF